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Background: Post-herpetic neuralgia (PHN) is the most common complication of herpes zoster (shingles). As a chronic
condition, PHN can have a substantial adverse impact on patients’ lives. However, UK-specific data concerning the
burden of PHN on individual patients, healthcare systems and wider society, are lacking. As the first UK-wide
cross-sectional study of its kind, The Zoster Quality of Life (ZQOL) study was designed to address these concerns.
Methods: Patients (n = 152) with a confirmed diagnosis of PHN (defined as pain persisting≥ 3 months following rash
onset) and aged ≥50 years were recruited from primary and secondary/tertiary care centres throughout the UK. All
patients completed validated questionnaires, including the Zoster Brief Pain Inventory (ZBPI), the Medical Outcomes
Study Short-Form 36 (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Treatment Satisfaction with Medication
(TSQM) questionnaire. Where available, mean patient population scores on these questionnaires were compared to
scores derived from age-matched normative samples to quantify the burden associated with PHN.
Results: Despite numerous consultations with healthcare professionals and receiving multiple medications for the
management of their PHN, the majority of patients reported being in pain ‘most of the time’ or ‘all of the time’. A total
of 59.9% (n = 91) of all PHN patients reported pain in the preceding 24 hours to assessment at levels (ZBPI worst
pain≥ 5) typically considered to have a significant impact on Health Related Quality of Life (HRQoL). Accordingly,
scores for SF-36 and EQ-5D indicated significant deficits in HRQoL among PHN patients compared to age-matched
norms (p < 0.05) and patients reported being dissatisfied with the perceived efficacy of therapies received for the
management of PHN. Increased pain severity was observed among older participants and higher levels of pain severity
were associated with greater HRQoL deficits.
Conclusions: The inadequate relief provided by PHN therapies available in the UK is associated with a significant
burden among PHN patients in terms of pain severity and deficits in HRQoL which may persist for years. Therefore,
alternative means such as prevention of shingles and PHN, are essential for reducing the impact on individual patients,
healthcare systems and society as a whole.Background
Herpes zoster (HZ) or “shingles” is a viral condition
resulting from reactivation of latent varicella-zoster virus
(VZV) which is responsible for childhood ‘chickenpox’.
Based on available data (1991–2000), it is estimated that
there are 225,000 new cases of HZ in England and
Wales alone [1]. Incidence of HZ increases with age,
with the majority of cases occurring in patients over
50 years of age [2,3] and the risk of developing HZ being* Correspondence: adam.gater@adelphivalues.com
2Adelphi Values, Cheshire, UK
Full list of author information is available at the end of the article
© 2014 Serpell et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.50% or more in those aged 80 years and over [4]. HZ is
characterised by a painful, unilateral, dermatomal rash.
This rash most commonly presents on the trunk, but
may present across any dermatome; this includes the tri-
geminal dermatome which extends across the eye and
may result in HZ with ocular involvement (i.e. Herpes
Zoster Ophthalmicus, HZO). Typically, HZ is an acute
experience with the distinctive rash and associated pain
resolving within one month of presentation [2]. How-
ever, despite treatment and resolution of the HZ rash,
approximately 10-20% of all HZ patients [4] continue to
experience pain for 90 days or more following HZ rashLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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aged 60 years and over. This is referred to as post-
herpetic neuralgia (PHN) and is the most common com-
plication of HZ [5,6].
PHN is a neuropathic syndrome which manifests as
ongoing pain along the cutaneous nerve/s located in the
area of prior HZ rash and typically involves one or more
of the following types of pain: spontaneous aching or
burning; paroxysmal shooting; and allodynia and hyper-
algesia [7]. While in the majority of cases this pain will
resolve within a year of initial rash presentation, for
some patients the pain may persist for five years or more
[8]. As expected, given the relationship to HZ, the inci-
dence of PHN increases markedly with age [9,10]. How-
ever, incidence is also linked to the severity of the pain
experienced during the HZ episode. Those patients ex-
periencing the highest levels of acute pain during HZ
presentation are most at risk of developing PHN [11].
PHN is also more prevalent amongst female than male
HZ sufferers [12,13].
Past cross-sectional, epidemiological studies have dem-
onstrated that the pain and resulting discomfort associ-
ated with PHN have a substantial, and negative, impact on
patients’ Health-related Quality of Life (HRQoL) along
with their ability to engage in daily activities [7,11,14,15].
As a chronic condition, care provision for PHN patients
in terms of visits to primary care (general practitioner cen-
tres) and outpatient secondary/tertiary care centres (spe-
cialist pain clinics and ophthalmologists), inpatient visits
(hospitalisations) and prescriptions constitutes a substan-
tial cost to healthcare systems [13,16-21]. Furthermore,
PHN is also associated with important indirect costs, pri-
marily in terms of loss of productivity for patients and
caregivers [20,22].
To date, only limited real-world evaluation of the bur-
den of HZ and PHN specific to UK patients has been
conducted. Furthermore, the research that has been con-
ducted is limited by relatively small sample sizes and a
lack of geographic representation [22]. In particular, in-
formation pertaining specifically to the burden of PHN
in UK patients is notably absent. To address this, the
Zoster Quality of Life (ZQOL) study was designed to as-
sess the clinical characteristics, patient-reported burden
and wider societal burden associated with HZ and PHN
within the UK. As a chronic condition, the patient-
reported impact, clinical management and economic costs
associated with PHN are quite distinct from HZ and war-
rant particular attention. PHN-specific information de-
rived from the ZQOL study is therefore outlined herein.
Therefore, the objectives of the current study were to
generate evidence regarding the following:
1. Disease presentation and disease history in UK PHN
patients;2. Burden of PHN for UK patients aged 50 years and
over in terms of subjective experience of pain and
HRQoL impact;
3. Economic burden associated with PHN in terms of
healthcare resource (e.g. prescribed medical
interventions, time spent with healthcare
professionals etc.);




The ZQOL study adopted a cross-sectional observa-
tional design involving data collection from HZ/PHN
patients and their treating doctors. No medical product
or device in addition to standard care was administered
to study patients, nor did participation in the study ne-
cessitate any change from standard of care.
Recruitment
A total of 150 PHN patients were targeted for recruitment
to the ZQOL to ensure sufficient power for the compari-
son of Patient Reported Outcome (PRO) data collected
from study participants to published aged-matched nor-
mative values for the respective instruments. This served
as the primary statistical analyses for the study. Adequacy
of the study sample size for this purpose was verified via
100,000 Monte Carlo simulations, using the Hochberg
(1988) Step-up Procedure to control for family-wise error
rate in multiple comparisons [23].
The management of HZ and PHN is largely based in
primary care (i.e. general practice), but some patients
(particularly those with long-lasting PHN) may be referred
to secondary/tertiary care centres (e.g. specialist pain
clinics) [24]. Whilst past studies have failed to identify sig-
nificant differences between patients treated in primary or
secondary/tertiary centres [14,25], patients were recruited
from a combination of both types of centre throughout
England, Scotland, Wales and Northern Ireland, in order
to avoid any potential bias in patient selection.
Consecutive patients presenting at the site as part of
routine clinical practice were considered for participa-
tion in the study. Frequency of presentation of PHN
cases was expected to be greater at secondary care cen-
tres and therefore fewer secondary care sites than pri-
mary care sites were targeted for inclusion in the study.
Patient eligibility for participation in the study was
ascertained by doctor completion of a study-specific case
report form (CRF). There exists no universally agreed
definition for PHN, but dermatomal pain or allodynia
persisting, recurring or arising 90 days after the onset of
the HZ rash is a commonly used definition and consid-
ered more conservative than alternative definitions based
on persisting or recurrent pain for 30 days. In addition
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50 years or over were eligible for participation in this
study. This is consistent with data suggesting that the in-
cidence and severity of HZ and PHN increases signifi-
cantly within this age range [2].
To ensure ecological validity of the study, extensive
exclusion criteria (as would typically be adopted in a
clinical trial) were not employed. However, to protect
the integrity of study findings, PHN patients with health
impairments that may make it difficult for them to
complete the required battery of PRO instruments (e.g.
deficits in cognitive functioning or visual impairments)
were excluded from participation. Similarly patients who
had taken part in a clinical trial related to HZ/PHN, pain
and/or immunomodulation therapy in the past 6 months
or who were previously experienced neuropathic pain in
the dermatomal region of their HZ rash prior to the on-
set of HZ were also excluded so to not bias study find-
ings. Of note, PRO instruments were only provided in
English and non-English speakers were excluded from
participation in the study.
Study procedures
Prior to recruitment of study patients, all site staff re-
ceived formal training in study procedures. This included
procedures for administering PRO questionnaires to pa-
tients to ensure standardisation and minimisation of miss-
ing data (e.g. ensuring that patients do not receive
additional help from anyone when completing the ques-
tionnaires and that all questionnaires are thoroughly
checked for completeness). In addition, as a pre-requisite
of site participation, all site staff were required to demon-
strate evidence of completion of good clinical practice
(GCP) training.
Once informed consent had been obtained and partici-
pant eligibility confirmed, patients were asked by study
staff to complete a combination of existing validated
PRO questionnaires as well as a study-specific socio-
demographic questionnaire. All questionnaires were bound
in a study booklet to ensure standardisation of presenta-
tion and order of completion among all patients.
Study questionnaires
Data were collected using the following PRO questionnaires.
Patient socio-demographic questionnaire
Used to collect patient socio-demographic data (age, gen-
der, ethnicity, living situation, education level and employ-
ment status) and data concerning patients’ experiences
of PHN.
Zoster brief pain inventory (ZBPI)
The ZBPI is designed specifically to evaluate pain intensity
due to HZ (which may include allodynia and pruritus) andthe extent that this may interfere with respondent’s activ-
ities of daily living [26]. The instrument comprises 15
items taken from the Brief Pain Inventory-Short Form
(BPI-SF), a well-validated PRO measure applied in a broad
spectrum of medical conditions [27] and includes four
items assessing ‘Pain severity’ and seven items assessing
‘Pain interference’. All items comprising these subscales are
assessed via 11-point numerical rating scales (NRS) ranging
from 0 (no pain/does not interfere) to 10 (pain as bad as
you can imagine/completely interferes). Prior research has
shown the ZBPI to be a reliable and valid assessment of
pain severity and impact for use in HZ and PHN patients
[26] and the instrument has been utilised in prior cross-
sectional and prospective investigations [11,22,28].
MOS 36-item short-form health survey (SF-36) standard form
The SF-36 is a standardised generic questionnaire that
consists of 36 items evaluating HRQoL [29]. The psy-
chometric validity of the SF-36 is well-established. In
particular, the SF-36 has demonstrated validity for use in
HZ and PHN populations [14,30]. Items explore the fol-
lowing eight dimensions: physical functioning, role func-
tioning due to physical problems, role functioning due
to emotional problems, bodily pain, general health per-
ceptions, vitality, social function and mental health. Two
summary scores, the Physical Component Summary
(PCS) and Mental Component Summary (MCS), can
also be calculated. Scores for the eight scale dimensions
and two summary scores were calculated using norm-
based scoring (NBS) algorithms which employ a linear
T-score transformation with mean = 50 and standard de-
viation = 10 – making it possible to meaningfully com-
pare scores across domains/summary scores [31].
The EuroQoL 5 dimensions questionnaire (EQ-5D)
The EQ-5D is a standardised generic questionnaire com-
prising 5 items that are used to provide a simple descrip-
tive profile and a single index value for health status
(ranging from 0–1): EQ-5D Health State Index (HSI)
[32]. In addition, the EQ-5D also includes a patient-
completed visual analogue scale (VAS), which records the
respondent’s self-rated health (SRH) on a vertical scale
where the endpoints are labelled from 0 (‘worst imagin-
able health state’) to 100 (‘best imaginable health state’).
Treatment satisfaction questionnaire for medication (TSQM)
version II
The TSQM Version II is an 11-item questionnaire de-
signed to assess patients’ satisfaction with various aspects
of their medication, including side effects (3 items + 1 yes/
no item), effectiveness (2 items), convenience (3 items)
and overall treatment satisfaction (2 items) [33]. Items are
assessed using 5-point and 7-point Likert scales ranging
from ‘Extremely dissatisfied’ to ‘Extremely satisfied’, but
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whereby higher scores indicate greater levels of patient
satisfaction. The TSQM has not been used previously in
HZ or PHN populations, but has been psychometrically
validated in a number of diverse patient populations [33].
To complement and facilitate interpretation of PRO
data, additional information was collected for each patient
via a doctor-completed CRF. This CRF included informa-
tion concerning patients’ socio-demographic characteris-
tics (e.g. BMI) and clinical presentation of PHN (e.g. time
since formal diagnosis). In addition, information concern-
ing patients’ medication and treatment history (including
frequency of consultations, hospitalisations, referrals and
additional investigations) was also collected.
Ethics
The ZQOL study was designed and conducted in ac-
cordance with the principles set forth in the Declaration
of Helsinki [34]. In accordance with current research
governance frameworks in the UK, ethical approval of
the study was obtained from the National Research
Ethics Service (NRES) before data collection began. Fur-
thermore, as the study involved use of National Health
Service (NHS) staff, premises, resources and data, local
R&D management approval was obtained from the re-
spective NHS local authorities before research began at
each site [35]. Finally, informed consent was obtained
from patients prior to the collection of data from them-
selves or their doctor and all data were handled in ac-
cordance with the 1998 Data Protection Act.
Statistical analyses
All planned statistical analyses were specified a priori in
a formally developed Statistical Analysis Plan (SAP). All
study data were subject to extensive quality control
checks prior to the conduct of analyses. In accordance
with developer instructions, if missing data for a SF-36
domain was ≤ 50% then data were imputed using the
mean of participants’ responses to the completed items
[29]. In the absence of developer instructions, missing
data for the ZBPI, SF-36 (where >50%), EQ-5D and
TSQM were not imputed and, where item scores were
missing, relevant domain scores were not calculated.
To quantify the burden associated with PHN, mean SF-
36 and EQ-5D scores from ZQOL study samples were
compared to published age-matched normative values for
the respective questionnaires as primary statistical ana-
lyses for the study [36,37]. The statistical significance of
differences was investigated via the conduct of unifactorial
tests. Differences of equal to or greater than 0.5 standard
deviation units of a baseline or comparator score were
characterised as clinically meaningful [38-40].
In addition, a number of sub-analyses were conducted
upon patient scores on the composite domains of theZBPI (pain severity and pain interference), SF-36 (PCS
and MCS) and EQ-5D (HSI and SRH) to test a number
of pre-specified hypotheses. Specifically, prior research
has indicated that reports of PHN pain severity increase
with age [13]. The association between patient age and
reported pain severity, pain interference and HRQoL im-
pact was investigated via calculation of Spearman Rho
correlation coefficients. Previous evidence research has
indicated differential reports of pain severity, pain inter-
ference and HRQoL impact by gender across a range of
medical conditions (including HZ and PHN ) [25,41].
To test this hypothesis, mean composite scores among
male and female patients were compared using unifac-
torial tests. Prior research has also indicated that pain
interference and HRQoL impact are greatest among pa-
tients reporting the greatest levels of pain [15]. To test
this hypothesis, ZBPI pain interference, SF-36 and EQ-
5D composite scores were compared among groups of
patients stratified according to empirically confirmed
categorisations of scores on the ‘Worst pain’ item of
the ZBPI: none (0); mild (1–4); moderate (5–6); severe
(7–10) [42]. ZBPI ratings of ‘worst pain’ were considered
as past research has indicated that ratings of ‘worst pain’
are the more reliable than ratings of ‘average’ or ‘current’
pain [26].
Finally, In order to explore potential predictors of
pain and HRQOL (as assessed by composite scores for
the aforementioned PRO questionnaires), a series of
ordinary least squares (OLS) regression analyses were
conducted. Independent predictor variables included:
socio-demographic variables (age, gender, ethnicity, BMI);
time with formal diagnosis of PHN; diagnosis of Herpes
Zoster Ophthalmicus (HZO); antiviral prescription within
72 hours of rash presentation; level of analgesics used as
defined according to the World Health Organisation
(WHO) analgesic ladder (level 1: non-opioid vs. level 2/3:
weak/strong opioids) [43]; hospitalisations (binary –
Yes/No); co-morbidities; and ZBPI ‘Worst pain’ item
scores. Assumptions of the OLS models (specifically nor-
mal distribution of errors, collinearity of independent vari-
ables and absence of extreme outliers) were verified prior
to the conduct of analyses.
Regression analyses were performed using the statis-
tical package R. All other analyses were conducted using
STATA software version 10.1
Results
Recruitment and participant socio-demographic
characteristics
A total of 152 PHN patients were recruited to the ZQOL
study from a combination of primary care and secondary
care sites between April 2010 and May 2011. A total of
82 patients were recruited from 25 primary care sites
with an average of 3.28 patients recruited from each site
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8 secondary care sites with average 8.75 patients re-
cruited from each site (range 1–20).
Socio-demographic and clinical characteristics for the
total study sample are presented in Table 1.
Disease presentation
PHN patients reported experiencing pain in the area of
their HZ rash for an average of 3.5 years (41 months,
range 1–473). The majority of ZQOL study participants
(59.8%; n = 91) had been suffering from PHN for one
year or more. Among ZQOL study patients, the PHN
pain most commonly affected more than one site of the
body (61.2%; n = 93) and most frequently presented on
the chest / rib cage (66.4%; n = 101), head and neck
(49.3%; n = 75) and abdomen / flanks (31.6%; n = 48) (see
Figure 1).
Reports from patients indicated that this pain was per-
sistent in nature, being present ‘Most of the time’
(36.8%; n = 56) or ‘All the time’ (29.6%; n = 45). The
terms most frequently selected by PHN patients to de-
scribe their pain were ‘sensitive’ (55.9%; n = 85), ‘tender’
(46.7%; n = 71), ‘burning’ (43.4%; n = 66), ‘aching’ (38.2%;
n = 58) and ‘stabbing’ (33.6%; n = 51).
In addition to pain, findings from the ZQOL study re-
veal that patients with PHN also experience a range of
other symptoms. In particular, symptoms of fatigue
(61.8%; n = 94), muscle weakness (27.6%; n = 42), change
in bowel movements (23.0%; n = 35) and an upset stom-
ach and nausea (23.0%; n = 35) were commonly experi-
enced by study participants.
Quantification of pain experienced by PHN patients: ZBPI
At the time of the study visit, 80.9% (N = 123) of PHN
patients reported experiencing pain in the previous
24 hours and 59.9% (n = 91) of all PHN patients gave
ratings of ‘Worst pain’ experienced in the past 24 hours
that are indicative of significant HRQoL burden (i.e.
worst pain score ≥ 5) [26,44]. Consideration of mean
scores for individual items comprising the ZBPI pain
interference scale revealed the greatest impact of pain
on PHN patients was in terms of ‘Enjoyment of life’,
‘Mood’ and ‘Sleep’ (Figure 2).
Calculation of Spearman rho correlation coefficients
indicated a small but statistically significant positive rela-
tionship between age and ZBPI pain severity scores.
However, no significant association between age and
ZBPI pain interference scores were observed (Table 2).
Comparisons of ZBPI pain severity and pain interference
scores for male and females revealed no significant dif-
ferences (Table 2). As expected, a significant linear rela-
tionship was observed in mean pain interference scores
for patients classified according to empirically confirmed
cut-offs for pain severity (Table 2).Prediction of ZBPI composite scores via ordinary least
squares (OLS) regression analyses revealed that pa-
tient use of level 2/3 analgesics (r2 = 0.053), patient
age (r2 = 0.043) and time since formal diagnosis of PHN
(r2 = 0.032) were able to explain 13.8% of the variance in
ZBPI pain severity composite scores (Table 3). Similar
regression analyses revealed that patient ratings of ‘worst
pain’ (r2 = 0.245), use of level 2/3 analgesics (r2 = 0.052)
and the presence of a psychological/psychiatric disorder
(r2 = 0.030) accounted for 38.8% of the variation in pain
interference scores.
PHN impact on HRQoL: SF-36
PHN patients demonstrated significant and clinically
meaningful deficits on all SF-36 domain and summary
scores (except for physical functioning where only statis-
tically significant deficits were observed) compared to
values derived from an age-matched normative popula-
tion (Figure 3).
Calculation of Spearman rho correlation coefficients
revealed a significant inverse relationship between pa-
tients’ age and PCS scores (i.e. lower HRQOL with in-
creasing age). However, no significant association between
patient age and MCS scores was observed (Table 2). PCS
and MCS scores were lower for female PHN patients,
compared to male patients. However, differences were not
significant. A significant linear relationship was observed
between PCS and MCS scores (the latter also clinically
meaningful) and patient ratings of ZBPI ‘worst pain’ classi-
fied according to empirically confirmed cut-offs for pain
severity (Table 2).
OLS regression analyses revealed use of level 2/3 anal-
gesics (r2 = 0.042) the presence of a metabolic/endocrine
disorder (r2 = 0.041) and patients’ age (r2 = 0.034) ex-
plained 12.4% of the variance in PCS scores (Table 3).
Similar regression analyses revealed that patient ratings
of ‘worst pain’ (r2 = 0.086), presence of a psychological/
psychiatric disorder (r2 = 0.082), presence of a respira-
tory disorder (r2 = 0.031), time since formal diagnosis
of PHN (r2 = 0.025) and patients’ BMI (r2 = 0.024)
accounted for 23.1% of the variance in MCS scores
(Table 3).
PHN impact on HRQoL: EQ-5D
Consideration of individual EQ-5D scores indicated that
‘Pain’ was the most prevalent problem for patients hav-
ing been reported by 90.1% of participants (Figure 4).
Significant and clinically meaningful deficits were ob-
served for Self-Rated Health (62.0 vs 77.3; p < 0.001) and
Health state Index (0.65 vs. 0.78: p < 0.001) scores among
PHN patients compared to age matched norms.
Calculation of Spearman rho correlation coefficients
revealed no significant association between patients’ age
and Self-Rated Health scores. However, a significant
Table 1 PHN ZQOL study patients: socio-demographic data
Characteristic PHN patients
(n = 152)
Age years – mean (Range) 71.5 (50 – 96)
Gender n (%)
male 57 (37.5%)
female n (%) 95 (62.5%)




Mixed race 1 (0.7%)
Comorbidities n (%)








Highest level of education n (%)
Secondary school or less 69 (45.4%)
O level or equivalent 21 (13.8%)
A level or equivalent 10 (6.6%)
Vocational 30 (19.7%)
Undergraduate degree 10 (6.6%)
Post graduate degree 9 (5.9%)
Other 3 (2.0%)
Work status n (%)
Full or part time employment 21 (13.8%)
Retired 120 (78.9%)
Unable to work due to post-herpetic neuralgia 3 (2.0%)
Unable to work for other medical reasons 5 (3.3%)
Other 3 (2.0%)
Living situation n (%)
Living alone 53 (34.9%)
Living with partner 90 (59.2%)
Living with partner and children 2 (1.3%)
Living with children 2 (1.3%)
Living with friends 1 (0.7%)
Living in a communal residence 0 (0%)
Living with family 4 (2.6%)
Years since formal diagnosis of PHN – mean (SD) 3.57 (5.11)
Current prescribed treatment by type n (%)
Antidepressant 90 (59%)
WHO Level 1 analgesic 84 (55%)
Table 1 PHN ZQOL study patients: socio-demographic data
(Continued)
WHO Level 2 analgesic 76 (50%)
Local anaesthetic/analgesic 34 (22%)
Topical analgesic 26 (17%)
WHO Level 3 analgesic 14 (9%)
Miscellaneous 37 (24%)
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and Health State Index scores (Table 2). Comparison of
Self-Rated Health and HSI scores for males and females
revealed no significant differences. A significant linear
relationship between Self-Rated Health and Health State
Index scores (the latter of which was also clinically
meaningful) was observed for patients classified accord-
ing to empirically confirmed cut-offs for pain severity
(Table 2).
OLS regression analyses indicated that patient-reported
levels of ‘Worst pain’ (r2 = 0.044) and use of level 2/3 anal-
gesics (r2 = 0.026) were the only significant predictors of
Self-Rated Health scores, explaining just 7.3% of the
variance in scores (Table 3). By comparison, the pres-
ence of a psychological/psychiatric disorder (r2 = 0.042),
patient-reported levels of ‘Worst pain’ (r2 = 0.133) and
patient use of level 2/3 analgesics (r2 = 0.031) were able
to explain 23.3% of the variance in Health State Index
scores (Table 3).
Productivity losses in PHN patients
Only 13.8% of PHN patients (n = 21) in the ZQOL study
were currently in full or part-time employment at the
time of the study, with the vast majority of participants
(78.9%; n = 120) indicating that they were now retired.
Despite this fact, considerable productivity losses were
evident among ZQOL study participants with reports
from participants indicating a mean of 6.4 days (range
0–31) per month when they were unable to take part in
their usual activities due to their PHN.
Impact of PHN on medical resource use
Clinician reports indicated that PHN patients were pre-
scribed multiple medications for the management of
their condition. The average number of different medi-
cations being taken by ZQOL study participants with
PHN was five. Antidepressants (predominantly the tri-
cyclic antidepressant amitriptyline - although not li-
cenced for use as a treatment of PHN in the UK) and
anticonvulsants (e.g. pregabalin and gabapentin) were
the most common treatment prescribed by doctors for
the management of PHN (59.2%; n = 90). Level 1 analge-
sics (55.3%; n = 84) were the next most commonly pre-
scribed treatment followed by level 2 analgesics (50.0%;
n = 76), local anaesthetics/analgesics (22.4%; n = 34) and
Figure 1 Area of body affected by PHN among ZQOL study patients (n = 152).
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of PHN patients reported taking non-prescribed medi-
cations for the management of their PHN. The most
common non-prescribed medications used by PHN pa-
tients were paracetamol (14.9%) and ibuprofen (2.6%).
Also of note, consultation of medical records indicated
that the majority of PHN patients (59.2%; n = 90) had
received an antiviral during the treatment of their initial
HZ episode.Figure 2 ZBPI domain and component scores among PHN ZQOL stud
(pain as bad as you can imagine) ^ Individual items and domains scored 0Based on patient reports, the average total number of
consultations with a healthcare professional related to
PHN following diagnosis was 9.5 visits per patient
(SD = 19.5). PHN patients for the ZQOL study were
recruited via referrals from primary care centres (n = 72)
and secondary/tertiary care centres (n = 80). Nearly half
(47%; n = 72) of PHN patients, however, had consulted an-
other healthcare professional (most commonly a secondary
care pain clinic n = 35) prior to seeing their currenty patients. Individual items and domains scored 0 (no pain) to 10
(does not interfere) to 10 (completely interferes).
Table 2 PHN pain severity/interference (ZBPI) and HRQOL impact (SF-36 & EQ-5D): ZQOL study subgroup analyses
Outcome variable














(n = 64) p
Zoster Brief Pain Inventory (ZBPI)
Pain severity 0.2112 ** 4.1 4.0 NS N/A N/A N/A N/A N/A
Pain interference 0.1365 NS 2.6 3.1 NS 0.2 1.3 2.8 4.7 ***†
Short-Form Health Survey 36 (SF-36)
SF-36 Physical Component Summary (PCS) −0.2904 *** 39.2 37.9 NS 42.1 41.9 37.3 35.5 *
SF-36 Mental Component Summary (MCS) −0.0527 NS 45.0 43.0 NS 47.8 49.5 46.6 37.7 ***†
EuroQoL 5-Dimensions (EQ-5D)
EQ-5D Self-Rated Health (SRH) −0.1506 NS 63.7 61.0 NS 65.5 69.7 62.0 56.6 *
EQ-5D Health State Index (HSI) −0.1724 NS 0.54 0.56 NS 0.70 0.73 0.65 0.38 ***†
NS p ≥ 0.05, * p < 0.05; ** p < 0.01; *** p <0.001. † = clinically meaningful difference.
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http://www.hqlo.com/content/12/1/92healthcare professional. Additional investigations had been
requested in 12.5% of patients (n = 19). Investigations re-
quested included full blood counts (n = 16) and tests of
renal function (n = 7) and inflammation (n = 6). Only two
patients reported being hospitalised due to PHN.Table 3 PHN pain severity/interference (ZBPI) and HRQOL imp
regression analyses
Dependent variable Significant predictor (Indepe
variables
Zoster Brief Pain Inventory (ZBPI)
Pain severity Analgesic level 2, 3
Age
Length of time with formal diagn
Pain interference ZBPI Worst pain
Analgesic level 2, 3
Psychological/psychiatric disorder
Short-Form Health Survey 36 (SF-36)
Physical Component Summary (PCS) Analgesic Level 2, 3
Metabolic/endocrine disorder
Age
Mental Component Summary (MCS) ZBPI Worst pain
Psychological/psychiatric disorder
Respiratory disorder
Length of time with formal diagn
Body Mass Index (BMI)
EuroQoL 5-Dimensions (EQ-5D)
Self-Rated Health (SRH) ZBPI Worst pain
Analgesic level 2, 3
Health State Index (HSI) ZBPI Worst pain
Psychological/psychiatric disorder
Analgesic level 2, 3Treatment satisfaction among PHN patients (TSQM)
PHN patients were classified into five groups according
to use of medications for the management of PHN:
Level 1 analgesics (e.g. paracetamol, non-steroidal anti-
inflammatory drug, Aspirin); Level 2 analgesics (e.g.act (SF-36 & EQ-5D): ZQOL ordinal least squares (OLS)
ndent) Beta r2 P > [t] 95% CI 95% CI Model
Lower Upper Adj R2
1.293 0.053 0.004 0.430 2.156 13.8%
0.056 0.043 0.008 0.015 0.098
osis of PHN 0.008 0.032 0.023 0.001 0.015
2.839 0.245 0.000 2.097 3.580
38.8%1.278 0.052 0.001 0.554 2.002
1.005 0.030 0.009 0.253 1.758
−4.578 0.042 0.009 −7.986 −1.170
12.4%−4.960 0.041 0.010 −8.719 −1.202
−0.203 0.034 0.018 −0.371 −0.035
−7.947 0.086 0.000 −11.948 −3.946
23.1%
−8.061 0.082 0.000 −12.226 −3.896
6.892 0.031 0.020 1.087 12.698
osis of PHN −0.034 0.025 0.035 −0.066 −0.002
0.423 0.024 0.039 0.022 0.825
−8.887 0.044 0.010 −15.577 −2.197
7.3%
−6.700 0.026 0.045 −13.237 −0.163
−0.242 0.133 0.000 −0.337 −0.147
23.3%s −0.141 0.042 0.005 −0.238 −0.043
−0.115 0.031 0.016 −0.208 −0.022
Figure 3 SF-36 domain and component scores among PHN ZQOL study patients compared to UK population norms. No *p≥ 0.05;
*p < 0.05; **p < 0.01; ***p < 0.001. † = clinically meaningful. PF = Physical functioning, R-P = Role-physical, BP = Bodily pain, GH = General health, V =
Vitality, SF = Social functioning, R-E = Role-emotional, MH=Mental health, PCS = Physical component summary, MCS =Mental component summary.
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http://www.hqlo.com/content/12/1/92weak opioids); Local anaesthetic/analgesic; Topical anal-
gesic; Antidepressants/anticonvulsants. Across all groups,
TSQM scores indicated that patients were least satisfied
with the perceived effectiveness of treatment and most
satisfied with the convenience of treatment. No significant
or clinically meaningful differences were observed be-
tween patients receiving different treatment for the man-
agement of their PHN (Figure 5).Figure 4 Percent of PHN patients reporting any problem on EuroQol-Discussion
While the patient-reported burden of PHN has been ex-
plored in past real-world studies, information on the
burden of PHN as experienced by UK patients is lacking.
The ZQOL study is the first study to evaluate the burden
of PHN from the perspective of UK patients, providing
data that are important for informing decisions by individ-
ual healthcare professionals, local health authorities and5 dimensions (EQ-5D) domains.
Figure 5 Treatment satisfaction questionnaire for medication (TSQM) domain scores among PHN study patients, categorized according
to treatment prescribed for the management of PHN.
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in the UK.
Understanding the presentation of PHN, experience of
pain and HRQOL burden in UK PHN patients
Age and gender distributions of the ZQOL study sample
are consistent with prior epidemiological investigations
of the incidence of PHN in the UK and previous studies
in the US, Canada and Europe [7,11,14,15]. Notably,
when compared to the HZ ZQOL study population,
PHN patients were (on average) older and more likely to
be female [45]. These findings are consistent with prior
research identifying age and gender as predictive factors
of PHN [46,47].
While PHN has a single well-defined cause, the under-
lying pathophysiology and presentation may vary be-
tween patients and within patients over the course of
the disease [48]. Amongst ZQOL participants, PHN was
characterised by ‘persistent’ pain most commonly present-
ing on the chest and ribs (66.4% of cases). Consistent with
prior research, the majority of patients (53.3%; n = 81) re-
ported experiencing pain in response to something touch-
ing their skin (i.e. tactile allodynia) [49]. Other symptoms
(including fatigue, muscle weakness, change in bowel
movements and nausea) were also frequently reported
and in contrast to prior research which suggests that such
symptoms occur in <20% of patients [22].
Past research has demonstrated that patients with fa-
cial HZ or Herpes Zoster Ophthalmicus (HZO) are at
greatest risk of developing PHN [47]. It is interesting to
note, therefore, that a greater proportion of PHN cases
were located on the head and neck (49.3%) among
ZQOL study participants compared to HZ (30.1%) study
participants [45]. Furthermore, while PHN may emerge
in a single dermatome, the majority of ZQOL studyparticipants (61.2%; n = 93) felt pain in more than one
site of the body with pain often extending to nearby der-
matomes. The pervasive nature of PHN is evident by the
fact that the majority of patients in the ZQOL study
(59.8%) had been suffering from PHN for one year or
more (average 3.5 years). This is in contrast to evidence
suggesting that PHN resolves within one year in most
cases [8] and has considerable implications for patient
health and costs associated with medical care.
Results from the ZQOL study indicated that more
than half of study participants with PHN (59.9%) re-
ported pain at levels typically considered indicative of
significant HRQOL burden [26]. Mean pain scores in
this population were similar to those reported in prior
investigations in Europe, the US and Canada [7,11,14,15].
Consistent with existing evidence, a significant association
between participant age and reported pain severity was
observed [13,15]. However, in contrast to prior research
that has noted higher reported levels of pain severity in fe-
male patients compared to male patients [25,41], no sig-
nificant gender differences in ZBPI scores were observed
among ZQOL study participants.
In the literature published to date, the degree of bur-
den experienced by PHN patients has rarely been inter-
preted with reference to standardised scores of HRQoL
obtained from normative populations [14]. Findings
from the ZQOL study indicate that PHN patients dem-
onstrate statistically significant and clinically relevant
deficits on all facets of HRQOL (physical and mental/
affective components) compared to age-matched UK
norms. Of note, in contrast to the findings observed
among HZ patients, significant deficits in the SF-36 do-
main of physical functioning (encompassing difficulties
with mobility, self-care and physical activities) compared
to age-matched norms were evident among PHN patients
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PHN patient’s age and HRQoL deficits on SF-36 domains
related to physical functioning only. It is likely that this
could be a reflection of general age-related morbidity to
which PHN may be a contributory factor. Consistent with
the differences observed among normative populations
[50], SF-36 and EQ-5D scores were generally lowest
among female PHN patients, however differences com-
pared to male PHN patients were non-significant.
Economic burden of PHN
As a chronic condition, PHN is associated with signifi-
cant direct and indirect costs, as supported by findings
from prior retrospective reviews of medical records and
databases [13,16-21]. Direct costs associated with treat-
ment of PHN in the UK (including medication costs,
doctor visits and hospital admissions), for example, have
previously been estimated at approximately £340 per
episode (2009) [13]. Existing data concerning the eco-
nomic burden of PHN are limited, however, because
they are based on retrospective review of data for pa-
tients presenting in primary care only. While many pa-
tients with PHN are treated in primary care, some
patients (particularly those with long-lasting PHN) may
be referred to secondary/tertiary care centres (e.g. spe-
cialist pain clinics) [24]. Furthermore, such retrospective
database reviews only reference direct costs and do not
provide an indication of indirect costs which can often
be equally as important in chronic diseases. Therefore
the true costs and economic burden of PHN may in fact
be much higher.
Consultations with healthcare professionals have previ-
ously been identified as the primary cost driver in PHN.
ZQOL study participants reported having seen a health-
care professional an average of 9.5 times regarding their
PHN which supports this notion. Medication costs are
another significant driver, again supported by the fact
that many participants in the ZQOL study were receiv-
ing multiple medications for the management of their
PHN. Findings from the study, however, indicated that
additional investigations and hospitalisations associated
with PHN were a rare occurrence, supporting past re-
search indicating that these factors are only marginal
contributors to direct costs associated with PHN [13].
The majority of patients in the ZQOL study were re-
tired and therefore the indirect costs of PHN, specifically
in relation to paid employment and work productivity,
were minimal. Of the small number of patients who
were working, however, almost all reported some impact
on their ability to work. As the average age of retirement
increases in the UK, it would be reasonable to expect
that the impact of PHN on work productivity and absen-
teeism may become more pronounced in the future.
Consistent with deficits reported by PHN patients inrelation to physical functioning and mobility, consider-
able impairments in the ability to complete activities of
daily living were also widely reported. Many participants
in the ZQOL study were living with someone else and,
as a result of these impairments, it is reasonable to ex-
pect that a significant proportion of patients may need
regular assistance from informal caregivers. The impact
of providing care to a patient both during the acute
presentation of HZ and during any long-term complica-
tions (e.g. PHN), however, remains largely unexplored
but may be another contributor to indirect costs associ-
ated with the diseases.
Treatment evaluation
Current therapeutic management of PHN centres upon
alleviation of pain associated with PHN. Clinician re-
ports from the ZQOL study supports findings from prior
research, which indicates that the treatment of PHN in
clinical practice typically requires more than one neuro-
pathic pain medication. A previous investigation by
Oster et al. (2005) suggested that patients were generally
dissatisfied with their treatment for PHN [15] but to
date there has been no attempt to quantify patient satis-
faction with HZ and PHN medications using standar-
dised assessments of treatment satisfaction.
Findings from the ZQOL study indicate that despite
the availability of various options for pain relief, PHN re-
mains difficult to manage [51,52], with many patients
still experiencing significant and clinically relevant levels
of pain. As a consequence, patients with PHN report dis-
satisfaction with the efficacy of current pain treatments.
Furthermore, while PHN patients indicate relative satisfac-
tion with the convenience of dosing schedules for pain re-
lief medication, the reliance upon multiple methods of
pain relief is a complicating factor for many elderly pa-
tients. It can increase the incidence of the side-effects and
potential drug interactions associated with concomitant
medication use. As many of these patients may also be re-
ceiving treatment for a range of co-morbid conditions, the
impact of polypharmacy on treatment satisfaction and
other patient outcomes should also be considered.
As life expectancy throughout the developed world
continues to rise, increasing attention is being paid to
the concept of ‘healthy ageing’. Given the challenges as-
sociated with managing PHN, preventative strategies for
shingles and associated complications (including PHN)
should be considered as a means of enabling patients to
remain active in old age and minimising the individual
patient and societal burden associated with the condi-
tion. Existing guidelines for healthcare professionals pro-
mote the use of antivirals for the management of HZ
episodes [53]. When administered within 72 hours of
rash onset, antivirals have been shown to promote rash
healing and reduce pain severity in acute HZ [54-56].
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for an impact of antiviral therapies on PHN, with their
efficacy for prevention of PHN considered modest at
best [57]. In line with this, 59.2% of PHN patients in the
ZQOL study reported having receiving antivirals for the
treatment of their preceding HZ episode. There is there-
fore a need to consider opportunities for prevention and
alternative strategies for pain management to reduce the
burden of PHN.
The VZV vaccine, Zostavax® (shingles (herpes zoster)
vaccine (live)) has been approved by US Food and Drug
Administration (FDA) and European Medicines Agency
(EMA) for prevention of HZ (“zoster” or shingles) in
patients aged 50 years and above. Clinical evidence re-
garding the efficacy of the VZV vaccine has indicated
that in addition to reducing the burden of illness asso-
ciated with HZ by 61.1%, the vaccine also reduced the
incidence of PHN by 66.5% [58]. Use of such a vac-
cine, therefore, could reduce the burden of illness
associated with PHN by reducing the number of inci-
dent cases.
ZQOL study limitations and opportunities for further
research
As the first UK-wide of its kind, the ZQOL study pro-
vides valuable insights into the burden of PHN in the
UK. Nonetheless, there still remain a number of gaps in
the understanding of the burden of PHN and opportun-
ities for further research.
Firstly, inconsistencies with disease definition and rec-
ognition present challenges to determining the true bur-
den of PHN among UK patients. For example, there
exists debate around the definition of PHN. Further-
more, experiences during the ZQOL study, indicate that
variation in record-keeping practices between centres (in
terms of systems used and information recorded) and
the lack of unique identifiers or codes in electronic-
record systems present challenges to the identification
and recruitment of PHN participants [59]. Past research
has also indicated that as many as 80% of patients with
PHN may not have this diagnosis specified within ad-
ministrative systems [18].There is a need, therefore, for
greater recognition and appreciation of PHN so as to
further understand the true burden of PHN for patients
and society.
Secondly, it should be noted that, despite the recruit-
ment of PHN patients from regional sites throughout
the UK, the proportion of non-Caucasian patients in the
ZQOL study (1.4%) is lower than UK population esti-
mates and less than reported in prior studies in this area
[15]. That non-English speaking PHN patients were ex-
cluded from the study may, in part, account for the
decreased representation of non-white ethnic groups
within the ZQOL study. There is also evidence to suggestthat VZV infection is less prevalent among certain ethnic
groups (e.g. Black African-Americans) [60,61] and those
born and raised in non-temperate climates [62]. Nonethe-
less, as a multi-cultural society, follow-up work to under-
stand the burden of PHN among ethnic minority patients
in the UK would be needed to provide a complete under-
standing of the burden of PHN to UK patients, the health-
care system and society.
Furthermore, it should be acknowledged that there are
disadvantages that are inherent to cross-sectional study
designs and that apply to the ZQOL study. For example,
by investigating patients who already have PHN at a sin-
gle point in time, it is difficult to infer cause and effect
between the development of PHN and HRQOL deficits.
Only an association can be determined. In addition,
when comparing to age-matched norms the assumption
(in the current study) is that observed differences are
due to the presence of PHN. However, it must be appre-
ciated that in such studies it is not practically possible to
formally account for underlying differences between the
study and normative populations or unmeasured factors
which may contribute to these observed differences.
Finally, while information collected using formal PRO
questionnaires provides a valid means of ‘quantifying’
the burden of HZ, qualitative research exploring the
‘lived experience’ of PHN from a patient’s perspective
would be beneficial for further understanding the bur-
den and unmet needs among PHN patients. However, to
the authors’ knowledge no qualitative accounts of the
experiences of PHN within the scientific literature have
been published to date.Conclusions
Data from the ZQOL study provide further evidence
that, as a common and chronic complication of HZ,
PHN has a significant impact of patients’ lives and may
result in significant costs for healthcare providers. Data
from this study also highlight current unmet needs
among PHN patients and inadequacy of current treat-
ments in the management of PHN, reinforcing the need
for effective means of prevention and alternative strat-
egies for pain management.Abbreviations
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